ALDOA inhibition slowed ALS progression in mice by reducing glycolysis-linked cell death
Original source
ALDOA Promotes Glycolysis and NLRP3/GSDMD Pyroptosis to Accelerate ALS Progression. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Mouse
Population inferred from the title and abstract by Compass.
Related topics
Blocking aldolase A (ALDOA) reduced glycolysis and extended survival in mice modelling amyotrophic lateral sclerosis (ALS). The treatment also slowed disease progression and reduced activation of a pathway linked to inflammatory cell death in motor neurons. Similar effects were observed in TDP-43-deficient laboratory cells.
Why this matters
The findings identify ALDOA as a possible treatment target and suggest a mechanism linking altered energy use to motor-neuron death. This was shown in mice and cells, not people, so it does not currently change ALS treatment or establish that ALDOA inhibition is safe or effective in patients.
Limitations and context
This is a primary research study using a TDP-43 mouse model and TDP-43-deficient laboratory cells. The supplied report does not provide the animal numbers or establish effects in people. Human studies would be needed to assess whether ALDOA inhibition is safe and beneficial in ALS.